Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai.
Background & objectives: Information available on HIV-2 and
dual infection (HIV-1/2) is limited. This study was carried out among
HIV positive individuals in an urban referral clinic in Khar, Mumbai,
India, to report on relative proportions of HIV-1, HIV-2 and HIV-1/2 and
baseline characteristics, response to and outcomes on antiretroviral
Methods: Retrospective analysis of programme data (May 2006-May 2009) at Khar HIV/AIDS clinic at Mumbai, India was done. Three test algorithm was used to diagnose HIV-1 and -2 infection. Standard ART was given to infected individuals. Information was collected on standardized forms.
Results: A total of 524 individuals (male=51%; median age=37 yr) were included in the analysis over a 3 year period (2006-2009)--489 (93%) with HIV-1, 28 (6%) with HIV-2 and 7(1%) with dual HIV-1/2 infection. HIV-2 individuals were significantly older than HIV-1 individuals (P<0.001). A significantly higher proportion of HIV-2 patients and those with dual infections had CD4 counts <200 cells/[micro]l compared to HIV-1. HIV-2 individuals were more likely to present in WHO Clinical Stage 4. Of the 443 patients who were started on ART, 358 (81%) were still alive and on ART, 38 (8.5%) died and 3 were transferred out. CD4 count recovery at 6 and 12 months was satisfactory for HIV-1 and HIV-2 patients on protease inhibitor based regimens while this was significantly lower in HIV-2 individuals receiving 3 nucleoside reverse transcriptase inhibitors.
Interpretation & conclusions: In an urban HIV clinic in Mumbai, India, HIV-2 and dual infections are not uncommon. Adaptation of the current national diagnostic and management protocols to include discriminatory testing for HIV types and providing access to appropriate and effective ART regimens will prevent the development of viral resistance and preserve future therapeutic options.
Key words ART--HIV-1--HIV-2--Mumbai--treatment outcomes
|Article Type:||Clinical report|
HIV infection (Care and treatment)
HIV infection (Diagnosis)
HIV infection (Development and progression)
Immune response (Research)
|Publication:||Name: Indian Journal of Medical Research Publisher: Indian Council of Medical Research Audience: Academic Format: Magazine/Journal Subject: Biological sciences; Health Copyright: COPYRIGHT 2010 Indian Council of Medical Research ISSN: 0971-5916|
|Issue:||Date: Dec, 2010 Source Volume: 132 Source Issue: 6|
|Topic:||Event Code: 310 Science & research|
|Geographic:||Geographic Scope: India Geographic Code: 9INDI India|
HIV type I (HIV-1) and type 2 (HIV-2) are very closely related but
differ in pathogenicity, natural history and therapy. HIV-1 is more
easily transmitted and consequently accounts for the vast majority of
global HIV infections. The less transmissible HIV-2 was thought to be
largely confined to West Africa (where it is thought to have originated)
(1,2) but has spread to parts of Europe and India (3-5).
When compared to HIV-1, HIV-2 infected individuals have a much longer asymptomatic stage, slower progression to AIDS (6-8), slower decline in CD4 count (6,9,10) lower mortality (7,11) , lower rate of vertical transmission (12-14) and smaller gains in CD4 count in response to antiretroviral treatment (ART) (15-17).
Serologic reactivity to HIV-1 and HIV-2 (HIV 1/2) has also increased in HIV-2 endemic areas over the past decade (18,19). In terms of antiretroviral drug regimens, HIV-2 is intrinsically resistant to non nuclesoside reverse transcriptase inhibitors (NNRTI) such as nevirapine and efavirenz and not all the protease inhibitors (PIs) provide good viral suppression (15).
Since the introduction of ART, several published papers (particularly from Africa) have described the clinical characteristics, response and treatment outcomes of HIV-1 infected patients on ART (19-22). In contrast, there is a dearth of published information on HIV-2 (23-24) (and dual HIV-1/2). Information on the distribution of HIV-2 and dual infection across the Indian subcontinent is limited and current surveillance by the National Programme does not pick up this information (24). The current national guidelines and the diagnostic and treatment algorithms do not allow for discrimination in the diagnosis of HIV infection by type or provide for treatment alternatives for HIV 2 and dual infected persons. From a public health perspective, it is important to assess the characteristics as well as response to ART for HIV-2 and dual infections.
We therefore carried out a study among HIV positive individuals in an urban referral clinic in Mumbai, India to report on relative proportions of HIV-1, HIV-2 and HIV-1/2, and baseline characteristics, response to and outcomes on ART.
Material & Methods
Study setting and population : This retrospective study was done between May 2006 and May 2009 at Khar HIV/AIDS clinic in Mumbai, Maharashtra State, India. This clinic is managed by Medecins Sans Frontieres (MSF).
MSF started an HIV project in Mumbai in February 2006 in collaboration with the Mumbai district authorities to provide access to populations who did not have access to the public system namely: HIV2, HIV-TB co-infection, Hepatitis B co-infection and drug resistant tuberculosis.
HIV positive patients diagnosed elsewhere are also referred to the MSF clinic where a discriminatory HIV-test is offered free-of charge to identify the type of HIV infection. HIV testing involves a three test algorithm. This includes Microparticle Enzyme Immunoassay (ABBOTT-AXSYM, Mumbai, India), Enzyme Immunoassay (MICROELISA-J Mitra, Mumbai, India) and Rapid Immunochromatography (TriDot, Mumbai, India). Tridot discriminates between HIV-1 and HIV-2. Confirmatory Western blot is done in the MSF Clinic for all the samples positive for HIV-2 or -1 and 2. All HIV-positive individuals undergo a full clinical and immunological assessment.
The study population for determining relative proportions of HIV types included all consecutive people living with HIV (PLHA) registered in the MSF clinic, while response to ART and treatment outcomes were assessed among all consecutive patients who started ART. The Khar clinic is open to all patients in Mumbai irrespective of geographical residence.
Antiretroviral therapy: Apart from pregnant women, HIV-positive individuals were eligible for ART if they presented in WHO Clinical Stage 3 (with CD4 count equal or less than 350 cells/[micro]l), WHO stage 4 irrespective of CD4 count or have a CD4-lymphocyte count <200 cells/[micro]l (irrespective of WHO stage (2,5). HIV-infected pregnant women were initiated on ART when their CD4-lymphocyte count was [less than or equal to]350 cells/[micro]l, regardless of clinical stage. Once started on ART patients were reviewed by a clinician 2 wk later and monthly thereafter. Individuals who started ART had their WHO clinical stage, CD4 cell count and weight measured at baseline and then at 6 monthly intervals.
For HIV-1, first-line ART was a fixed dose combination of stavudine (d4T) or zidovudine (AZT), lamuvudine (3TC) and nevirapine (NVP) or efavirenz (EFV). In case of double toxicity to zidovudine (AZT) and stavudine (d4T), the alternative treatment is tenofovir (TDF). In the event of renal failure (creatinine clearance <50) tenofovir (TDF) was replaced with abacavir (ABC).
For HIV-2, first-line ART was selected according to the background (previous history of intake) of ART. For ART naive patients, 3 nucloside reverse transcriptase inhibitors (NRTIs) were given: TDF and a fixed dose combination of zidovudine (AZT) and lamivudine (3TC). In case of renal failure, TDF was replaced with ABC.
For ART experienced patients, a PI based regimen was given which included indinavir (IDV), ritonavir (RTV) and fixed dose combination of stavudine (d4T) and lamuvudine (3TC). Boosted indinavir was preferred to lopinavir/ritonavir for HIV-2 infection based on previous information (15,26-29). Lopinavir/ritonavir (LPV/r) was given only in case of severe intolerance to IDV. For HIV-2 and HIV-1&2 co-infection, the first line treatment was a fixed dose combination of d4T and 3TC plus lopinavir/ritonavir (LPV/r), in the heat stable form. Lopinavir/ritonavir (LPV/r) in this case is preferred to indinavir because the disease is driven by HIV-1 infection.
Data collection and treatment outcomes: Structured forms were used to gather information on HIV status, HIV-type, WHO clinical stage and CD4 cell count at presentation. ART treatment outcomes were recorded on a monthly basis from Treatment cards. Data were entered and stored in the FUCHIA database system (FUCHIA, Epicentre, Paris, France). Data were collated on all patients from May 2006 and were censored at the end of June 2009.
Standardised treatment outcomes were monitored on a monthly basis and were defined as: alive and on ART (patient alive and on ART at the facility where he/she was registered); died (patient who had died for any reason while on ART), lost to follow up (patient who did not attend the clinic for one month or more after their scheduled follow up appointment); stopped treatment (patient known to have stopped treatment for any reason during treatment); transferred out (patient who had transferred-out permanently to another treatment facility).
Statistical analysis: Previous reports from India (3,4) have showed a HIV-2 prevalence of about 5 per cent. Assuming that the same proportion is applicable to our setting and the worst possible result that we would like to detect is 7 with a 95 per cent confidence interval and 2 per cent error, a total of at least 456 consecutive individuals was required.
Differences between groups were compared using the [chi square] test for categorical variables and the Wilcoxon rank-sum test for continuous variables. The level of significance was set at P<0.05. Data were analysed using the STATA/IC 10.0 software (Stata corporation, Texas 77845, USA).
This study received ethical clearance from the ethics review committees of the international Union Against TB and Lung disease and Medecins Sans Frontieres.
Cohort characteristics: A total of 611 individuals tested HIV-positive, of whom 87 did not have HIV-type specified and were therefore, excluded from the analysis. Among the remaining 524 individuals included in the study, 272 (52%) were male, (median age 37 yr, range: 2-65 yr). Nearly half (43%) reported earning a regular income, 96 (18%) were housewives, 33 (6%) were sex workers, 12 (2%) were students, 3 (1%) were businessmen and 156 (30%) were unemployed (Table I).
There were 489 (93%) individuals with HIV-1, 28 (6%) with HIV-2 and 7 (1%) with dual HIV-1/2 infection. HIV-2 individuals were significantly older (> 45 yr) than HIV individuals. A significantly higher proportion of HIV-2 patients and those with dual infections had CD4 counts <200 cells/[micro]l compared to HIV-1. Among HIV-1, HIV-2 and HIV-1/ 2 infections, 414 (85%), 25 (89%) and 4 (57%) started ART respectively.
Characteristics of patients on ART and immunologic outcomes: Among the 524 HIV-positive individuals with HIV-type classified, 443 started ART. Of these, 414 (93%) had HIV-1, 25 (6%) had HIV-2 and 4 (1%), HIV-1/2. Contrary to the trend seen at baseline, HIV-1 patients were generally older at ART initiation compared with HIV-2 patients. Ten (40%) HIV-2 patients had been started on a regimen of 3 NRTI and 15 (60%) started on a regimen of 2NRTIs and 1 PI (Table II).
The mean increase in CD4 for HIV-1 was 195, not statistically different from the one observed in HIV-2 patients treated with a PI-based regimen at 6 and 12 months (Fig.).
The immunological results obtained with a PI-based regimen were satisfactory both in naive and non naive patients. A slower but constant CD4 gain was observed in the patients with dual infection at 6 and 12 months. In contrast, a decline in CD4 count was seen in the group of HIV-2 patients treated with 3 NRTIs. In view of this decline, these patients were all switched subsequently to a PI based regimen.
Treatment outcomes censored at the end of June 2009 included: 358 (81%) alive and on ART, 38 (9%) deaths, 31 (7%) lost to follow up and 14 (3%) transferred out (Table II).
This is one of the first reports describing baseline characteristics and response to ART among patients with HIV-1, HIV-2 and dual HIV-1/2 in the routine setting of an HIV Clinic in Mumbai, India. Of particular relevance is the finding that HIV-2 and dual infections are not uncommon, and it is likely that the situation is similar in other clinics in the same setting. It is necessary that the Ministry of Health along with partners works towards revision and adaptation of the current diagnostic and management protocols for HIV. What is urgently needed is to (i) include discriminatory testing and diagnosis of all HIV types; (ii) increase access to discriminatory HIV-1 and HIV-2 test kits at HIV testing sites. Patients found to have dual infections should also have the possibility for access to confirmatory HIV type-testing at identified referral laboratories; and (iii) provide access to effective first-line ART regimens for both HIV-1, HIV-2 and dual infections in order to avoid the development of viral resistance that will compromise future therapeutic options particularly for HIV-2.
Surprisingly HIV-2 individuals presented with lower CD4 counts and a significantly higher proportion were in WHO Clinical Stage 4 when compared to HIV-1. This probably reflects delays in diagnosis which can be due to a slower progression of the disease or to a lack of systematic screening for HIV-2. In the absence of discriminatory HIV testing, HIV-2 individuals might be assumed to have HIV-1 and be wrongly placed on an ineffective ART regimen and progress in their illness before presenting to our clinic. Misdiagnosis of HIV-1/2 may also be a problem in many peripheral centres in Mumbai and accurate identification of dual HIV-1/2 infection remains a diagnostic challenge. Although limited by sample size, two (50%) of the four patients with dual infections died during ART and this might be related to late diagnosis and ineffective initial ART regimens. This is suggested as both patients were non naive and had very low baseline CD4 counts. Discriminating between HIV-1 and HIV-2 is relatively simple as the rapid HIV detection assays (if available) are sensitive and specific for HIV-1 and HIV-2. However, these assays lack specificity for dual HIV-1/2 infection. Different studies have shown that among individuals diagnosed as dual seropositive, often only HIV-1 or HIV-2 DNA is isolated (more often HIV-1), a phenomenon commonly thought to be explained by cross-reactivity (17,30,31). However, this has important management implications and all patients found with dual infections should ideally undergo confirmatory testing using polymerase chain reaction techniques or Western blot. These are currently not available in the government ART centres.
Despite the fact that baseline CD4 cell counts at ART initiation were relatively similar between the different serotypes, CD4 cell recovery appeared to be poorer for dual infected patients than for HIV-1 and HIV-2, at 6 and at 12 months. The trend in CD4 gain in HIV-2 patients who were on a PI regimen was encouraging considering that all these patients were ART exposed (previously exposed to NNRTIs based regimens). The reason for this can be the systematic use of indinavir as the standard PI for HIV-2 in our setting (22).
The failure of a 3NRTI regimen in terms of immunological recovery in our cohort was quite significant and highlights the need to review treatment options for HIV-2 infection. Considering that all HIV-2 patients who started 3 NRTIs were NNRTI naive, the failure could be due to an infection with non-naive virus (primary resistance), to undocumented previous exposure to double NRTIs (an ineffective first-line ART regimen containing an NNRTI) or due to an intrinsic incomplete suppression of viral loads on the triple NRTI regimen. This observation persuaded us to switch all the patients to a superior PI based regimen, and in future this will be the regimen of choice.
The strengths of this study are that: (i) loss to follow up was relatively low (7%), and (ii) the data came from a programme setting and were likely to reflect the operational reality on the ground. The limitations of the study included (i) limited number of patients and thus limited statistical power to detect statistically significant differences, (ii) a relatively short period of observation: the cohort thus needed to be followed up for a longer time period; and (iii) there were no data on viral load either at the start or during therapy.
In conclusion, in an HIV clinic in Mumbai, India, HIV-2 and dual infections are not uncommon and it is likely that the situation is similar in other clinics. An HIV testing strategy that discriminates between HIV types and access to effective first-line ART regimens must be considered to manage these patients effectively.
Authors thank to all the staff of their partner NGOs, MDACS (Maharashtra district aids control society) and NACO (national aids control organisation) for the collaboration and effort they are making to fight HIV-AIDS epidemic in India.
Conflict of interest: We have no conflict of interest to declare.
Received October 20, 2009
(1.) Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye-Ndiaye A, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343 : 943-6.
(2.) Horsburg CR, Holmbreg SD. The global distribution of human immunodeficiency virus type 2 (HIV-2) infection. Transfusion 1988; 343 : 943-6.
(3.) Rubsamen-Waigmann H, Maniar J, Gerte S, Brede HD, Dietrich U, Mahambre G, et al. High proportion of HIV-2 and HIV-1/2 double-reactive sera in two Indian states, Maharashtra and Goa: first appearance of an HIV-2 epidemic along with an HIV-1 epidemic outside of Africa. Zentralbl Bakteriol 1994; 280 : 398-402.
(4.) Kulkarni S, Thakar M, Rodrigues J, Banerjee K. HIV-2 antibodies in serum samples from Maharashtra state. Indian J Med Res 1992; 95 : 213-5.
(5.) Babu PG, Saraswathi NK, Devapriya F, John TJ. The detection of HIV-2 infection in southern India. Indian J Med Res 1993; 97 : 49-52.
(6.) Marlink R, Lessons from the second virus, HIV-2. AIDS 1996; 10 : 689-99.
(7.) Whittle H, Morris J, Todd J, Corrah T, Sabally S, Bangali J, et al. HIV-2-infected patients survive longer than HIV-1 infected patients. AIDS 1994; 8 : 1617-20.
(8.) Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265 : 1587-90.
(9.) Jaffar S, Wilkins A, Ngom PT, Sabally S, Corrah T, Bangali JE, et al. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16 : 327-2.
(10.) Schim van der Loeff M, Jaffar S, Aveika A, Sabally S, Corrah T, Harding E, et al. Mortality of HIV-1, HIV-2 and HIV-1/ HIV-2 dually infected patients in a clinic-based cohort in the Gambia. AIDS 2002; 16 : 1775-83
(11.) Matheron S, Courpotin C, Simon F, Di Maria H, Balloul H, Bartzack S, etal. Vertical transmission of HIV-2. Lancet 1990; 335 : 1103-4.
(12.) Andreasson PA, Dias F, Naucler A, Andersson S, Biberfeld G. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 1993; 7 : 989-3.
(13.) Adjorlolo-Johnson G, Decock KM, Ekpini E, Vetter KM, Sibailly T, Brattegaard K, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272 : 462-6.
(14.) De Cock K, Zadi F, Adjorolo G, Diallo M, Sassan-Morokro M, Ekpini E, et al. Retrospective study of maternal HIV-1 and HIV-2 infections and child survival in Abidjan, Cote d'Ivoire. BMJ 1994; 308 : 441-3.
(15.) Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. JAntimicrob Chemother 2006; 57 : 709-13.
(16.) Matheron S, Damond F, Benard A, Taieb A, Campa P. CD4 recovery in treated HIV-2 infected adults is lower than expected: results from the France ANRS CO5 HIV-2 cohort. AIDS 2006; 20 : 459-62.
(17.) Rouet F, Ekouevi DK, Inwoley A, Chaix M-L, Burgard M, Bequet L, et al. Field evaluations of a rapid human immunodeficiency virus serial serological testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2 and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol 2004; 42 : 4147-53.
(18.) Ampofo WK, Koyanagi Y, Brandful J, Ishikawa K, Yamamoto N. Seroreactivity clarification and viral load quantification in HIV-1 and HIV-2 infections in Ghana. J Med Dent Sci 1999; 46 : 53-62.
(19.) Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundu G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival and drug resistance. Lancet 2002; 360 : 34-40.
(20.) Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40 : 336-43.
(21.) Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18 : 887-95.
(22.) Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia--feasibility and early outcomes. JAMA 2006; 296 : 782-93.
(23.) Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22 : 873-82.
(24.) NACO. National AIDS HIV Sentinel Surveillance and HIV Estimation in India 2007. A Technical Brief' and 'Note on HIV sentinel surveillance and HIV estimation. Available from: http://www.nacoonline.org/Quick_Links/HIV_Data/, accessed on August 1, 2009.
(25.) World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings. Treatment guidelines for a public health approach. Geneva, Switzerland: WHO; 2006.
(26.) Witvrouw M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Antivir Chem Chemother 1999; 10 : 211-7.
(27.) Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9 : 3-12.
(28.) Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, et al. Antiretroviral therapy for HIV-2 infected patients. J Infect 2001; 42 : 126-33.
(29.) Adje-Toure C, Cheingsong R, Garcia-Lerma G, Eholie S, Borget MY, Bouchez JM, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17 (Suppl 3) : S49-S54.
(30.) Sagoe K, Mingle J, Affram R, Britton S, Dzokoto D, Sonnerborg A. Virological characterization of dual HIV-1/ HIV-2 seropositivity and infections in Southern Ghana. Ghana Med J 2008; 42 : 16-21.
(31.) Peeters M, Gershy-Damet G-M, Fransen K, Koffi K, Coulibaly M, Delaporte E, et al. Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d'Ivoire. Lancet 1992; 340 : 339-40.
Reprint requests: Dr R. Zachariah, Medecins sans Frontieres (Brussels operational center) Medical department (Operational research) 68 Rue de Gasperich, L-1617, Luxembourg firstname.lastname@example.org
Montaldo Chiara, Zachariah Rony *, Mansoor Homa, Varghese Bhanumati, Joanna Ladomirska, M. Manzi *, N. Wilson (+), Deshpande Alaka ** & A.D. Harries (#, ##)
Medecins sans Frontieres, Mumbai, India, * Medecins sans Frontieres, Medical Department (Operational Research), Operational Centre Brussels, Belgium, MSF-Luxembourg, Luxembourg, ** ART Centre, JJ Hospital Mumbai, India, (+) International Union against Tuberculosis & Lung Disease, South East Asia Office, New Delhi, India, (#) International Union against Tuberculosis & Lung Disease, Paris, France & (##) London School of Hygiene & Tropical Medicine, London, UK
Table I. Characteristics of individuals with HIV-1, HIV-2 and HIV-1/2 in MSF Khar Clinic (n=524) Variable HIV-1 HIV-2 P value n (%) n (%) (a,b) Total 489 (93) 28 (6) -- Sex Females 210 (43) 13 (46) 0.7 Males 252 (51) 15 (54) Transgender 27 (6) 0 -- Age (yr) < 15 36 (8) 1 (4) 0.6 15-29 96 (20) 1 (4) 0.03 30-44 293 (60) 14 (50) 0.29 45+ 64 (12) 12 (42) <0.001 Age, yr, median (IQR) 33 (31-42) 44 (40-48) <0.001 Marital status Single 110 (22) 6 (21) 0.9 Married 277 (57) 17 (61) 0.7 Widowed 88 (18) 5 (18) 0.9 Divorced/separated 14 (3) 0 (0) -- Baseline CD4 cell count (cell/[micro]l) < 50 25 (5) 2 (7) 0.93 50-199 165 (34) 21 (75) <0.001 200-349 232 (47) 1 (4) <0.001 [greater than or equal to] 350 67 (14) 4 (14) 0.8 Median (IQR) (n=5161) 221 (76-307) 143 (73-144) 0.08 WHO clinical stage I 151 (31) 0 (0) -- II 83 (17) 4 (14) 0.9 III 183 (37) 11 (39) 0.8 IV 72 (15) 13 (47) <0.001 Variable HIV-1&2 P value n (%) (a,c) Total 7 (1) -- Sex Females 2 (29) 0.7 Males 5 (71) Transgender 0 -- Age (yr) < 15 0 (0) -- 15-29 1 (14) 0.92 30-44 6 (86) 0.3 45+ 0 (0) -- Age, yr, median (IQR) 39 (31-43) 0.37 Marital status Single 1 (14) 0.9 Married 4 (58) 0.7 Widowed 2 (28) 0.8 Divorced/separated 0 (0) -- Baseline CD4 cell count (cell/[micro]l) < 50 (0) -- 50-199 6 (86) 0.01 200-349 1 (14) 0.1 [greater than or equal to] 350 0 -- Median (IQR) (n=5161) 127 (91-160) 0.3 WHO clinical stage I 2 (29) 0.7 II 0 (0) -- III 2 (29) 0.9 IV 3 (43) 0.1 IQR, interquartile range; ART, antiretroviral therapy; WHO, World Health Organization; (a) [chi square] test for categorical variables and Wilcoxon rank- sum test for continuous variables; (b) Comparing HIV-1 with HIV-2; (c) Comparing HIV-1 with HIV-1 & 2 Table II. Characteristics and treatment outcomes of patients on ART (>6 months) according to HIV type in Khar Clinic (n=443) Variable HIV-1 (a) HIV-2 P value n (%) n (%) (b,c) Total 414 25 -- Sex Females 231 (56) 11 (44) 0.2 Males 164 (40) 14 (66) 0.01 TG 19 (4) 0 Age (yr) <15 18 (4) 0 (0) -- 15-29 78 (19) 15 (60) <0.001 30-44 274 (66) 10 (40) <0.01 45+ 44 (11) Age, yr, median (IQR) 37 (33-43) 45 (41-49) 0.01 WHO clinical stage Stage I or II 185 (45) 5 (20) 0.01 (CD4<250 cells/[micro]l) Stage III 128 (31) 12 (48) 0.07 Stage IV 101 (21) 8 (32) 0.19 CD4 count, (cells/ [micro]l) < 50 73 (18) 3 (12) 0.6 50-199 244 (59) 21 (84) 0.01 200-349 87 (21) 1 (4) 0.03 >350 10 (2) 0 (0) -- Median (IQR) 189 (72-262) 96 (73-111) 0.03 ART regimen 2 NRTIs + 1 NNRTI 334 (81) 0 (0) -- 3 NRTIs 5 (1) 10 (40) < 0.001 2 NRTIs + PIs 75 (18) 15 (60) < 0.001 ART outcomes Alive on ART 333 (80) 25 (100) -- Dead 36 (9) 0 (0) Lost to follow up 31 (8) 0 (0) Transferred out 14 (3) 0 (0) Variable HIV-1&2 P value n (%) (b,d) Total 4 -- Sex Females 0 (0) -- Males 4 (100) 0.2 TG 0 -- Age (yr) <15 0 (0) 15-29 4 (100) 30-44 0 (0) 45+ Age, yr, median (IQR) 44 (39-43) 0.15 WHO clinical stage Stage I or II 0 (0) -- (CD4<250 cells/[micro]l) Stage III 2 (50) 0.7 Stage IV 2 (50) 0.8 CD4 count, (cells/ [micro]l) < 50 0 (0) -- 50-199 4 (100) 0.2 200-349 0 (0) -- >350 0 (0) -- Median (IQR) 114 (79-150) 0.4 ART regimen 2 NRTIs + 1 NNRTI 0 (0) 3 NRTIs 0 (0) 2 NRTIs + PIs 4 (100) 0.8 ART outcomes Alive on ART 2 (50) -- Dead 2 (50) Lost to follow up 0 (0) Transferred out 0 (0) IQR, interquartile range; ART, antiretroviral therapy; WHO, World Health Organization; NRTI, nucleoside reverse transcriptase inhibitors; NFV, nelfinavir; LPV/r, lopinavir/ritonavir; IDV, indinavir; NNRTI, non-nucleoside reverse transcriptase inhibitors; (a) 1 unknown outcome for HIV-1; (b) [CHI SQUARE] test for categorical variables and Wilcoxon rank-sum test for continuous variables; (c) Comparing HIV-1 with HIV- 2; d Comparing HIV-1 with HIV-1 & 2 Fig. Mean CD4 cell counts in patients on ART in Mumbai during follow up according to HIV type and ARV regimen. CD4 counts Baseline Months 6 12 18 24 30 36 HIV 1 159 278 325 380 367 395 358 HIV-2 114 102 91 (3 NRTI) HIV-2 78 171 254 (2 NRTI + 1 PI) HIV 1/ 2 98 134 171 164 264 (2NRTI+1PI) (a) Wilcoxon rank-sum test comparing HIV-1 with HIV 2; (b) Wilcoxon rank-sum test comparing HIV-1 with HIV 1/2; (c) wilcoxon rank-sum test comparing HIV-2 (3 NRTI) with HIV-2 (2 NRTI + 1 PI); NRTI, nucleoside reverse transcriptase enzyme; PI, protease inhibitor
|Gale Copyright:||Copyright 2010 Gale, Cengage Learning. All rights reserved.|